Published in Rheumatol Int on July 02, 2013
Targeting the inflammasome in rheumatic diseases. Transl Res (2015) 0.77
Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus. Nutr J (2015) 0.76
Omega-3: a double-edged sword for autoimmune diseases. Rheumatol Int (2013) 0.75
Dietary factors in rheumatic autoimmune diseases: a recipe for therapy? Nat Rev Rheumatol (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA (2012) 9.37
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) (2008) 5.50
N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med (2002) 4.33
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (1989) 4.02
The bimodal mortality pattern of systemic lupus erythematosus. Am J Med (1976) 3.47
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med (1993) 3.35
Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum (1999) 2.98
Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA (2001) 2.62
Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum (2009) 2.26
Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum (2000) 2.06
The composition of the Eskimo food in north western Greenland. Am J Clin Nutr (1980) 1.99
Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr (2004) 1.94
Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) (2006) 1.87
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr (2000) 1.77
Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol (1995) 1.60
Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: a metaanalysis and metaregression. J Rheumatol (2011) 1.52
Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb (1992) 1.52
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol (1995) 1.52
Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk (1999) 1.40
Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol (2004) 1.33
Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol (2002) 1.26
Fat, fish, fish oil and cancer. Br J Cancer (1996) 1.21
Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol (Tokyo) (1982) 1.18
Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol (1997) 1.17
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis (1999) 1.14
A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis (2007) 1.12
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2008) 1.12
Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord (2008) 1.07
A comparison of brachial artery flow-mediated vasodilation using upper and lower arm arterial occlusion in subjects with and without coronary risk factors. Clin Cardiol (2000) 1.05
Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem (2009) 0.98
Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus (2004) 0.97
Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb (1993) 0.96
Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects. Am J Clin Nutr (1992) 0.96
ω-3 fatty acids suppress inflammatory cytokine production by macrophages and hepatocytes. J Pediatr Surg (2010) 0.94
Increased TGF-beta and decreased oncogene expression by omega-3 fatty acids in the spleen delays onset of autoimmune disease in B/W mice. J Immunol (1994) 0.90
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) (2011) 0.90
Use of nonprescription medications for perceived cardiovascular health. Am J Prev Med (2006) 0.89
The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol (2004) 0.89
Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res (1995) 0.88
Direct protective effects of poly-unsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current: a mechanism for ischemia selectivity. Basic Res Cardiol (2007) 0.86
Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Int Immunopharmacol (2010) 0.85
Accelerated atheroma in lupus--background. Lupus (2000) 0.83
Maintenance of NF-kappaB activation in T-lymphocytes and a naive T-cell population in autoimmune-prone (NZB/NZW)F(1) mice by feeding a food-restricted diet enriched with n-3 fatty acids. Cell Immunol (2001) 0.82
ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study. Coron Artery Dis (2013) 0.77
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet (2006) 6.98
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
Toward interoperable bioscience data. Nat Genet (2012) 4.72
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A (2007) 4.71
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet (2004) 4.46
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med (2015) 3.63
ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect (2003) 3.39
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum (2004) 2.88
QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn (2004) 2.73
The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J (2008) 2.61
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med (2006) 2.53
Development of public toxicogenomics software for microarray data management and analysis. Mutat Res (2004) 2.29
Hydroxychloroquine in lupus pregnancy. Arthritis Rheum (2006) 2.27
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum (2009) 2.20
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA (2004) 2.19
Hepatitis c in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg (2002) 2.12
Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol (2015) 2.07
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. BMC Bioinformatics (2008) 1.98
Edematous erythema, subcutaneous plaques, and severe pain in the lower extremities in an immunocompromised patient. JAMA (2013) 1.97
Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet (2011) 1.92
Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol (2010) 1.89
Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) (2006) 1.87
Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation (2008) 1.80
Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet (2008) 1.80
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol (2013) 1.75
Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum (2011) 1.72
GOFFA: gene ontology for functional analysis--a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics (2006) 1.72
Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol (2007) 1.71
Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. J Rheumatol (2010) 1.69
DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin Cancer Res (2010) 1.69
Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol (2009) 1.67
Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum (2012) 1.66
Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl (2009) 1.65
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis (2002) 1.64
Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum (2010) 1.63
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum (2005) 1.59
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) (2013) 1.58
Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet (2011) 1.57
The SEEK model of pediatric primary care: can child maltreatment be prevented in a low-risk population? Acad Pediatr (2012) 1.56
Procoagulants and osteonecrosis. J Rheumatol (2003) 1.54
Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents (2009) 1.54
Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics (2011) 1.53
Intrafamilial transmission of hepatitis C in Egypt. Hepatology (2005) 1.53
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2012) 1.49
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. J Am Dent Assoc (2002) 1.49
Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 1.47
A novel mutation within the 2B rod domain of keratin 9 in a Chinese pedigree with epidermolytic palmoplantar keratoderma combined with knuckle pads and camptodactyly. Eur J Dermatol (2011) 1.44
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.43
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum (2005) 1.41
Influence of atrial function and mechanical synchrony on LV hemodynamic status in heart failure patients on resynchronization therapy. JACC Cardiovasc Imaging (2011) 1.41
Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. Chem Res Toxicol (2011) 1.41
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosus. J Rheumatol (2007) 1.39
Prednisone, lupus activity, and permanent organ damage. J Rheumatol (2009) 1.38
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 1.37
Technical reproducibility of genotyping SNP arrays used in genome-wide association studies. PLoS One (2012) 1.36
Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum (2012) 1.34
Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med (2006) 1.34
Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn (2011) 1.33
Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther (2009) 1.33
Decision forest: combining the predictions of multiple independent decision tree models. J Chem Inf Comput Sci (2003) 1.32
Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum (2012) 1.32
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect (2002) 1.31
Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol (2004) 1.30
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med (2005) 1.30
Identifying children at high risk for a child maltreatment report. Child Abuse Negl (2011) 1.29
Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics (2008) 1.29
Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2004) 1.28
Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J Nutr (2002) 1.27
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol (2012) 1.27
A novel role of Brg1 in the regulation of SRF/MRTFA-dependent smooth muscle-specific gene expression. J Biol Chem (2007) 1.26
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics (2005) 1.25
A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int (2009) 1.24
IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol (2012) 1.23
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum (2009) 1.23
The SWI/SNF chromatin remodeling complex regulates myocardin-induced smooth muscle-specific gene expression. Arterioscler Thromb Vasc Biol (2009) 1.22